Want to see IN:PAR full AI Analyst Report?
PAR Stock Chart & Stats
₹100.93
-₹2.28(-1.11%)
At close: 4:00 PM EST
₹100.93
-₹2.28(-1.11%)
Day’s Range― - ―
52-Week Range₹78.05 - ₹122.43
Previous CloseN/A
Volume42.53K
Average Volume (3M)31.06K
Market Cap
₹1.22B
Enterprise Value₹949.99
Total Cash (Recent Filing)₹418.43M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)9.3
Beta1.06
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.65
Shares Outstanding12,304,636
10 Day Avg. Volume60,109
30 Day Avg. Volume31,062
Financial Highlights & Ratios
PEG Ratio-3.82
Price to Book (P/B)0.86
Price to Sales (P/S)0.93
P/FCF Ratio6.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA zero-debt balance sheet materially lowers financial risk and preserves flexibility for multi‑year investment, M&A, or R&D without refinancing needs. This structural strength improves resilience in downturns and supports durable capital allocation decisions over the next 2–6 months and beyond.
Free Cash Flow GenerationConsistent positive free cash flow across reported periods indicates the business generates surplus cash after reinvestment. That persistent cash generation supports reinvestment, working-capital needs, and shareholder returns while providing a buffer for cyclical stresses and strategic initiatives over the medium term.
Profitability / ReturnsA mid‑teens net margin (approx. 12.6% in 2026) reflects durable pricing power or cost control versus peers, producing healthy returns on capital. Sustained profitability underpins internal funding capacity and supports ongoing operating investments and potential shareholder distributions over the coming months.
Bears Say
Inconsistent Revenue GrowthIrregular top-line growth reduces predictability for capacity planning and long-term investment. Variability across years can signal reliance on episodic product cycles or uneven market penetration, making it harder to scale operations sustainably and judge multi‑period demand trends.
Margin VolatilityCompression and volatility in gross and net margins point to sensitivity to input costs, product mix shifts, or pricing pressures. That instability undermines confidence in sustainable profitability and can limit the company's ability to consistently fund incremental investments or absorb competitive pricing shocks.
Uneven Cash ConversionRepeated instances where operating cash flow lagged net income indicate working-capital swings or timing issues. Uneven cash conversion can constrain short-term liquidity for capex or inventories and complicate capital allocation despite overall positive free cash flow, increasing operational funding risk.
Par Drugs and Chemicals Limited News
PAR FAQ
What was Par Drugs and Chemicals Limited’s price range in the past 12 months?
Par Drugs and Chemicals Limited lowest stock price was ₹78.05 and its highest was ₹122.43 in the past 12 months.
What is Par Drugs and Chemicals Limited’s market cap?
Par Drugs and Chemicals Limited’s market cap is ₹1.22B.
When is Par Drugs and Chemicals Limited’s upcoming earnings report date?
Par Drugs and Chemicals Limited’s upcoming earnings report date is Nov 11, 2026 which is in 101 days.
How were Par Drugs and Chemicals Limited’s earnings last quarter?
Currently, no data Available
Is Par Drugs and Chemicals Limited overvalued?
According to Wall Street analysts Par Drugs and Chemicals Limited’s price is currently Overvalued.
Does Par Drugs and Chemicals Limited pay dividends?
Par Drugs and Chemicals Limited pays a Notavailable dividend of ₹1.25 which represents an annual dividend yield of N/A. See more information on Par Drugs and Chemicals Limited dividends here
What is Par Drugs and Chemicals Limited’s EPS estimate?
Par Drugs and Chemicals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Par Drugs and Chemicals Limited have?
Par Drugs and Chemicals Limited has 12,304,636 shares outstanding.
What happened to Par Drugs and Chemicals Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Par Drugs and Chemicals Limited?
Currently, no hedge funds are holding shares in IN:PAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Par Drugs and Chemicals Limited
Par Drugs and Chemicals Limited is an Indian enterprise that focuses on the creation, production, and sale of active pharmaceutical ingredients (APIs) and specialized chemicals. Its comprehensive product line features a diverse array of compounds, such as magnesium salts, dried aluminum hydroxide gel, sodium aluminum silicate, precipitated silica, magnesium silicate, colloidal silicon dioxide, sucralfate USP, as well as various amorphous and custom-blended formulations. The company also extends its market presence through international exports. Founded in 1982, Par Drugs and Chemicals Limited is headquartered in Vadodara, India.
Technical Analysis
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Brooks Laboratories Limited
―
Vivimed Labs Limited
―